
- /
- Supported exchanges
- / US
- / PHAR.NASDAQ
Pharming Group NV (PHAR NASDAQ) stock market data APIs
Pharming Group NV Financial Data Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pharming Group NV data using free add-ons & libraries
Get Pharming Group NV Fundamental Data
Pharming Group NV Fundamental data includes:
- Net Revenue: 340 M
- EBITDA: 26 370 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: -0.0125
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharming Group NV News

Pharming Group provides update on previously announced G&A expense reduction plan
Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructurin...


Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based o...

CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
Shares of Cidara Therapeutics CDTX have skyrocketed 217.8% in the year so far, driven by positive updates from the development program of its only clinical-stage pipeline candidate, CD388, for the pre...

QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
Shares of uniQure N.V. QURE skyrocketed 247.7% on Wednesday after the company reported meeting key goals in the pivotal early to mid-stage study of its investigational gene therapy, AMT-130, for the t...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.